List of Excipients in Branded Drug MICAFUNGIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	MICAFUNGIN	micafungin	42023-229	CITRIC ACID MONOHYDRATE
Endo USA Inc	MICAFUNGIN	micafungin	42023-229	SODIUM HYDROXIDE
Baxter Healthcare Corporation	MICAFUNGIN IN SODIUM CHLORIDE	micafungin in sodium chloride	0338-9051	ANHYDROUS CITRIC ACID
Baxter Healthcare Corporation	MICAFUNGIN IN SODIUM CHLORIDE	micafungin in sodium chloride	0338-9051	SODIUM CHLORIDE
Baxter Healthcare Corporation	MICAFUNGIN IN SODIUM CHLORIDE	micafungin in sodium chloride	0338-9051	TRISODIUM CITRATE DIHYDRATE

Generic Drugs Containing MICAFUNGIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	micafungin sodium	0143-9361	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	micafungin sodium	0143-9361	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	micafungin sodium	0143-9361	SODIUM HYDROXIDE
Northstar Rx LLC	micafungin	16714-164	ANHYDROUS CITRIC ACID
Northstar Rx LLC	micafungin	16714-164	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in MICAFUNGIN?

# Of NDCs	Excipient
12	ANHYDROUS CITRIC ACID
1	CITRIC ACID MONOHYDRATE
13	LACTOSE MONOHYDRATE
13	SODIUM HYDROXIDE
2	WATER

Micafungin Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Micafungin is an intravenous echinocandin with a mature generic market and limited conventional patent protection. The commercial opportunity has shifted from API exclusivity to differentiated injectable presentations, excipient optimization, reduced preparation time, pediatric usability, storage stability, and hospital supply economics. The strongest targets are lactose-free formulations, ready-to-use or premixed products, lower-volume presentations, and packaging systems that reduce compounding steps without compromising micafungin stability.

What is the current formulation of micafungin?

Micafungin is marketed primarily as a sterile lyophilized powder for intravenous infusion. The reference product is Mycamine, developed by Astellas Pharma and approved by the FDA in 2005.

Attribute	Reference product profile
Active ingredient	Micafungin sodium
Drug class	Echinocandin antifungal
Route	Intravenous infusion
Dosage forms	50 mg and 100 mg single-dose vials
Formulation	Lyophilized powder for reconstitution
Core excipients	Lactose, citric acid, sodium hydroxide
Diluents	0.9% sodium chloride injection or 5% dextrose injection
Administration	Diluted intravenous infusion
Key use areas	Candidemia, invasive candidiasis, esophageal candidiasis, and prophylaxis of Candida infections in hematopoietic stem-cell transplant patients
Reference sponsor	Astellas Pharma US
FDA approval	Mycamine NDA 021506, approved March 16, 2005

The labeled inactive ingredients are lactose, citric acid, and sodium hydroxide. Sodium hydroxide is used for pH adjustment rather than as a substantial formulation component. The product is reconstituted before further dilution and infusion. It is not supplied as an oral product because micafungin has poor oral bioavailability and requires parenteral administration for systemic exposure. [1]

The formulation challenge is not simply dissolving micafungin. The development program must control reconstitution time, pH, aggregation, particulate formation, chemical degradation, vial adsorption, dilution stability, and compatibility with infusion materials.

What excipients are used in Mycamine and generic micafungin?

The principal excipient in the reference formulation is lactose. Citric acid provides buffering capacity, while sodium hydroxide adjusts the final pH. Generic products generally follow the reference formulation closely because the injectable product must meet stringent quality, bioequivalence, sterility, and pharmaceutical equivalence requirements.

Lactose

Lactose supports the lyophilized cake and contributes to the physical stability of the dried product. It is also commercially familiar, inexpensive, and widely accepted in sterile product manufacturing.

Its limitations create a potential differentiation point:

• It can raise concerns for patients with severe galactose intolerance or related metabolic disorders.
• It may require prominent labeling for hereditary galactose intolerance and glucose-galactose malabsorption.
• It may complicate positioning for neonatal, pediatric, or specialized hospital formularies.
• It does not differentiate a generic product because it is already used in the reference product.

A lactose-free formulation could replace lactose with another bulking or stabilizing system, such as mannitol, sucrose, trehalose, or a combination of excipients. The substitution would require full assessment of cake structure, reconstitution behavior, micafungin recovery, residual moisture, aggregation, and long-term stability.

Citric acid

Citric acid contributes to pH control and can affect micafungin stability and solubility. A formulation using phosphate, acetate, histidine, or another buffer could offer a potential patent position, but buffer substitution carries compatibility risks.

The relevant commercial question is whether an alternative buffer improves a measurable product attribute. A different buffer alone is unlikely to support a strong product franchise unless it produces a meaningful improvement in one or more of the following:

• Longer refrigerated or room-temperature stability
• Lower particulate burden
• Faster reconstitution
• Better compatibility with common infusion diluents
• Reduced interaction with container-closure materials
• Improved performance in ready-to-use systems

Sodium hydroxide

Sodium hydroxide is generally a pH-adjustment agent. It is not likely to provide a meaningful standalone commercial differentiator. Its importance is process control: small changes in pH can affect micafungin degradation, solubility, and aggregate formation.

What excipient strategies could differentiate micafungin?

The most credible excipient strategies are those connected to an identifiable hospital workflow or regulatory benefit.

1. Lactose-free lyophilized micafungin

A lactose-free product could use mannitol, sucrose, trehalose, or a mixed stabilizer system. The objective would be to preserve the reference product's reconstitution and infusion performance while removing lactose-related labeling constraints.

A development program would need to demonstrate:

• Equivalent micafungin content and purity
• Comparable or improved reconstitution time
• Acceptable cake appearance and mechanical integrity
• Low aggregation after reconstitution
• Equivalent infusion compatibility
• Stability under labeled storage conditions
• No clinically relevant change in excipient-related safety

This is the most straightforward excipient-based opportunity, but it may be difficult to establish a strong market premium because hospitals typically prioritize acquisition cost, supply continuity, and formulary interchangeability.

2. Ready-to-use liquid formulation

A ready-to-use product could eliminate vial reconstitution and reduce pharmacy preparation steps. The formulation would need to maintain micafungin stability in aqueous solution over a commercially useful shelf life.

Potential approaches include:

• Low-concentration aqueous solutions
• Buffered liquid formulations
• Prefilled infusion bags
• Pharmacy-ready containers
• Small-volume concentrates for automated compounding systems

The main technical barrier is long-term solution stability. A liquid product exposes micafungin continuously to water, container surfaces, oxygen, light, and temperature changes. The development program would need to control degradation products, visible and subvisible particles, extractables and leachables, and container adsorption.

A ready-to-use product could command a higher price than a conventional vial if it reduces pharmacy labor and medication-preparation risk. Its strongest customers would be hospitals with high antifungal utilization, centralized pharmacy operations, and pressure to reduce sterile-compounding workload.

3. Premixed infusion bags

A premixed bag could combine micafungin with an approved infusion vehicle, such as 0.9% sodium chloride or 5% dextrose. This would eliminate reconstitution and subsequent dilution.

Commercial advantages include:

• Fewer preparation steps
• Lower risk of reconstitution error
• Reduced staff exposure during compounding
• Lower need for pharmacy batching
• Simpler administration in intensive-care and transplant units

The formulation must address concentration, bag material, oxygen exposure, light protection, infusion duration, and storage. The product may also require a larger package configuration than a vial, increasing shipping and cold-chain costs.

Premixed bags are most attractive where nursing and pharmacy labor costs are high. They are less attractive where low-cost generic vials are routinely prepared in centralized batches.

4. Dual-chamber or on-demand reconstitution systems

A dual-chamber device could separate the lyophilized micafungin cake from the diluent until administration. This approach preserves dry-state stability while reducing manual reconstitution.

Potential benefits include:

• Longer shelf life than a liquid product
• Lower preparation burden
• Reduced contamination risk
• Improved portability for hospital use
• Potential integration with closed-system transfer devices

The main barriers are device cost, extractables and leachables, dose presentation, regulatory complexity, and manufacturing scale. The commercial case depends on whether the device reduces enough pharmacy and nursing labor to offset its cost.

5. Pediatric and neonatal presentations

Micafungin is used in pediatric and neonatal patients, but dosing is weight-based. A 50 mg or 100 mg vial may create substantial wastage when small doses are needed.

Potential opportunities include:

• Lower-strength vials
• More concentrated formulations
• Reduced dead-volume containers
• Dose-banded presentations
• Ready-to-use pediatric syringes for controlled hospital use

Lower-dose vials could reduce wastage but increase manufacturing, packaging, and inventory complexity. A concentrated formulation could reduce infusion volume, but the developer would need to establish tolerability, infusion-site compatibility, and reliable dose withdrawal.

What manufacturing and excipient barriers affect micafungin?

Micafungin is a complex semisynthetic echinocandin rather than a simple small-molecule tablet API. The drug contains a cyclic peptide-like structure and a lipid side chain, creating manufacturing and analytical requirements beyond those of conventional generic injectables.

Key barriers include:

Barrier	Commercial effect
Complex API synthesis	Limits the number of qualified API suppliers
Low tolerance for degradation	Raises stability and impurity-control requirements
Lyophilization sensitivity	Makes cycle development and scale-up material
Aggregate and particulate control	Increases release-testing burden
Container compatibility	Affects vial, stopper, bag, and tubing selection
Sterile manufacturing	Requires high capital and validated aseptic capacity
Global comparability	May require jurisdiction-specific formulation and manufacturing packages
Supply-chain concentration	Creates opportunity for reliable second-source supply

Excipient changes can alter the freeze-drying cycle, cake morphology, residual moisture, and reconstitution profile. A formulation that performs well at laboratory scale may fail during commercial lyophilization because of heat-transfer differences, vial loading, fill depth, or cycle duration.

A successful excipient strategy therefore needs to be developed together with the container-closure system and lyophilization process. The excipient composition alone may not provide the strongest intellectual property position.

What patents protect micafungin formulations and manufacturing?

The original micafungin patent estate was associated with Astellas and its predecessor companies and covered the active compound, echinocandin derivatives, pharmaceutical compositions, and manufacturing technology. The principal U.S. compound patent family associated with micafungin includes U.S. Patent No. 6,107,458. The core U.S. exclusivity period has expired.

Protection category	Current commercial relevance
Core micafungin compound	Expired in the United States
Basic pharmaceutical composition	Generally expired or no longer blocking routine generic entry
Original injectable formulation	Mature and vulnerable to generic competition
New excipient system	Potentially patentable if it produces unexpected or clinically relevant performance
Ready-to-use liquid formulation	Potentially protectable through composition, stability, packaging, and use claims
Premixed infusion bag	Potentially protectable through formulation and container-system claims
Pediatric low-dose product	Potentially protectable through concentration, dosing, and delivery claims
Manufacturing process	May remain commercially valuable as trade secret or process patent, even without blocking composition claims

An excipient patent is more defensible when it claims a defined composition linked to a measurable result. Examples include a particular stabilizer ratio that reduces aggregate formation, a buffer system that improves room-temperature stability, or a container formulation that maintains potency after prolonged storage.

A patent claiming only the use of a conventional excipient with micafungin may face novelty and obviousness challenges. The strongest claims would likely combine:

• Defined micafungin concentration
• Specific excipient ranges
• pH limits
• Lyophilized or liquid dosage form
• Container-closure material
• Reconstitution or dilution conditions
• Stability or impurity thresholds

What is the Orange Book status of micafungin?

Micafungin is an injectable small-molecule drug, so the relevant generic pathway is an abbreviated new drug application, not a biosimilar application. FDA-approved generic micafungin products have entered the U.S. market after the reference product's core exclusivity period.

The Orange Book analysis should focus on:

• Whether Mycamine has active listed patents
• Whether any listed patents cover a specific formulation or use
• Whether generic applicants submitted Paragraph IV certifications
• Whether any patent litigation triggered a 30-month stay
• Whether pediatric or hospital-use claims create residual market segmentation

For a mature product such as micafungin, generic entry risk is high. The practical barriers are more likely to involve sterile manufacturing capacity, supply reliability, API sourcing, and hospital contracting than enforceable composition patents. FDA Orange Book records and the Drugs@FDA application history are the controlling sources for current listing and approval status. [2,3]

Are there Paragraph IV challenges or patent litigation involving micafungin?

Micafungin's principal U.S. patent risk has passed from originator exclusivity to generic competition. Publicly significant litigation relating to the core Mycamine franchise is less commercially important than the product's current generic supply structure.

A new formulation developer could create Paragraph IV exposure if it relies on an active listed patent covering:

• A liquid formulation
• A premixed infusion product
• A new stabilizer system
• A particular method of administration
• A device or container system

For a conventional generic vial, the key risk is usually not a new Paragraph IV challenge but price erosion from multiple ANDA suppliers. For an improved formulation, the developer must assess whether the product would be marketed under an ANDA, a 505(b)(2) application, or another regulatory pathway. A substantial formulation change may require a 505(b)(2) application rather than a simple ANDA.

What FDA regulatory pathway applies to an improved micafungin formulation?

The pathway depends on how closely the proposed product matches the reference formulation.

ANDA

An ANDA is most suitable for a product that is pharmaceutically equivalent and bioequivalent to the reference product. This route supports conventional generic vials but provides limited flexibility for meaningful excipient or presentation changes.

505(b)(2)

A 505(b)(2) application is more suitable for:

• A ready-to-use liquid formulation
• A premixed infusion bag
• A new concentration
• A different container system
• A new dosing presentation
• A meaningful excipient change supported by clinical or bridging data

The regulatory value of a 505(b)(2) product increases if the new formulation improves administration, safety, stability, or adherence to hospital medication-use protocols.

Hospital-use product strategy

A company could also pursue a differentiated hospital product without seeking a broad therapeutic label change. The commercial case would center on workflow savings, supply continuity, and lower total cost of administration. The product still must satisfy FDA requirements for sterility, stability, container compatibility, labeling, and infusion administration.

How does micafungin compare with competing antifungals?

Micafungin competes primarily with caspofungin and anidulafungin within the echinocandin class. It also competes with liposomal amphotericin B and azole antifungals depending on infection, patient population, resistance profile, organ function, and route of administration.

Product	Route	Formulation opportunity	Key commercial issue
Micafungin	IV	Lactose-free vial, premix, ready-to-use bag, pediatric dose	Generic price competition
Caspofungin	IV	Reconstitution simplification, stability, pediatric packaging	Established generic competition
Anidulafungin	IV	Reconstitution and dilution workflow	Narrower product base
Liposomal amphotericin B	IV	Reconstitution, dilution, lipid-particle stability	Complex handling and toxicity management
Voriconazole	IV and oral	Solvent reduction, infusion compatibility	IV excipient and safety concerns
Isavuconazole	IV and oral	Formulation convenience and oral-to-IV transition	Higher-value branded positioning

Micafungin has a strong formulation rationale because it is already a hospital-administered IV product with repeated preparation steps. The opportunity is less compelling for a standard low-cost vial, where clinical substitution and tender pricing dominate.

Which commercial opportunities are most attractive?

The opportunities rank as follows:

Opportunity	Technical difficulty	Patent potential	Commercial attractiveness
Conventional generic lyophilized vial	Low to medium	Low	Medium, driven by volume
Lactose-free lyophilized vial	Medium	Medium	Medium
Lower-dose pediatric vial	Medium	Medium	Medium to high in specialty centers
Ready-to-use liquid	High	High	High if stability is achieved
Premixed infusion bag	High	High	High in large hospitals
Dual-chamber delivery system	High	High	Medium to high
Room-temperature-stable product	High	High	High where cold-chain costs matter
New oral micafungin product	Very high	High	Uncertain because of bioavailability barriers

The best near-term opportunity is a differentiated injectable product that reduces preparation labor while retaining a defensible stability or container-closure advantage. A lactose-free formulation may be easier to develop, but its pricing power is likely to be limited unless it is paired with a workflow benefit.

What revenue exposure does micafungin create for manufacturers?

Micafungin revenue is exposed to rapid generic erosion because:

• The reference product's core patent protection has expired.
• The product has no meaningful biosimilar barrier.
• Hospital buyers can use formulary substitution and tenders.
• Several manufacturers can compete through standard sterile injectable platforms.
• The product is administered in institutional settings where procurement is price-sensitive.

The reference product remains commercially relevant in hospitals, transplant centers, oncology facilities, and intensive-care units. Public company filings generally do not disclose micafungin revenue as a separate line item, so product-specific revenue exposure cannot be reliably quantified from consolidated reporting alone.

For manufacturers, the commercial value is more likely to come from portfolio economics than from micafungin alone. A company with existing sterile injectable capacity, hospital distribution, and antifungal contracting can use micafungin to improve manufacturing utilization and account coverage.

What geographic markets offer the best excipient opportunity?

The United States offers the clearest opportunity for differentiated injectable products because of the large hospital market, established 505(b)(2) pathway, and strong demand for pharmacy workflow products.

Europe and Japan may offer opportunities where:

• Hospital pharmacy labor costs are high
• Premixed products have procurement advantages
• National tenders reward supply reliability
• Pediatric or lactose-related labeling issues influence formulary decisions

Emerging markets may favor standard vials because acquisition cost dominates. A ready-to-use presentation may still succeed in private hospitals, transplant centers, and tertiary-care facilities, but premium pricing will be more difficult.

Geographic protection should combine formulation patents with manufacturing-process claims, device claims, and trade-secret controls. A formulation patent alone may not prevent a competitor from using a different stabilizer system to reach the same commercial objective.

Key Takeaways

• Micafungin is an IV echinocandin marketed as a lyophilized powder for reconstitution.
• Mycamine uses lactose, citric acid, and sodium hydroxide as inactive ingredients.
• The core U.S. micafungin patent estate is mature, and conventional generic entry risk is high.
• Biosimilar risk does not apply because micafungin is a small-molecule drug.
• The strongest excipient opportunities are lactose-free formulations, ready-to-use liquids, premixed infusion bags, and pediatric dose presentations.
• A meaningful patent position should link excipient composition to stability, reconstitution, aggregation, compatibility, or workflow performance.
• A standard generic vial is primarily a price and supply-chain play.
• A 505(b)(2) product may be better suited than an ANDA for major formulation or delivery changes.
• Hospital labor savings and reduced preparation risk are the main sources of premium commercial value.
• The principal competitive threats are generic price erosion, sterile manufacturing scale, API supply reliability, and hospital tender dynamics.

FAQs

Can lactose be removed from micafungin without changing the dose?

Yes, but replacing lactose requires reformulation and stability studies. The developer must show that the substitute maintains potency, purity, cake structure, reconstitution behavior, and infusion compatibility.

Is micafungin suitable for a prefilled syringe?

A prefilled syringe could be technically feasible for selected doses, but long-term liquid stability, adsorption, extractables and leachables, dose accuracy, and infusion compatibility would determine commercial viability.

Would a room-temperature micafungin product have strong market value?

Yes. Room-temperature stability could reduce cold-chain costs and simplify hospital inventory management. The value would be strongest if the product also reduced reconstitution or dilution steps.

Can a new micafungin excipient formulation receive three years of FDA exclusivity?

A 505(b)(2) product may qualify for three years of FDA exclusivity if approval is based on new clinical investigations conducted or sponsored by the applicant. The exclusivity analysis depends on the specific application and supporting studies.

Is micafungin manufacturing a barrier to generic competition?

Yes. The product requires complex API production, sterile injectable manufacturing, lyophilization, particulate control, and validated container-closure systems. These barriers limit the field of capable suppliers even though core patent protection has expired.

References

1. U.S. Food and Drug Administration. (2023). Mycamine (micafungin sodium) for injection prescribing information. Astellas Pharma US, Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.

4. U.S. Patent No. 6,107,458. (2000). Echinocandin derivatives. United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (2024). Applications covered by the regulatory exclusivity provisions and the patent certification provisions in the Federal Food, Drug, and Cosmetic Act. U.S. Department of Health and Human Services.